Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NIO Inc. (NIO) vs Novavax Inc (NVAX) Price & Performance

Novavax IncTrade

Price performance (Past 24H)

Key statistics

NIO Inc. vs Novavax Inc — how do they compare? NIO Inc. trades at $4.56 (market cap $11.59B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: NIO Inc. is far larger — about 8.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.

NIONVAX
Market Cap
$11.59B$1.31B
Sector
Consumer CyclicalHealth
52-Week High
$7.89$11.19
52-Week Low
$4.44$6.22
Enterprise Value
$10.82B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NIO Inc.

NIO's stock trades at $4.555, down 5.5% in the last session amid a bearish technical signal and negative cash flow trends. The company shows revenue growth with 2025 sales reaching $87.49 billion, but remains unprofitable with a net loss of $15.57 billion. Recent news highlights delivery growth and policy support for EVs in China, yet investor sentiment is mixed due to competitive pressures and high cash burn.

The outlook is cautious; while analyst consensus leans bullish with 54% buy ratings, fundamental weaknesses in profitability and negative equity pose significant risks. Upside depends on sustained revenue expansion and cost control, but volatility from market sentiment and execution challenges warrants careful monitoring for investors.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About NIO Inc.

NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.

Read more on NIO

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX